APA (7th ed.) Citation

Zhao, J., Tang, Y., Hu, X., Yin, X., Chen, Y., Chen, J., . . . Shen, P. (2024). Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma. Molecular Cancer, 23(1), 1. https://doi.org/10.1186/s12943-024-02044-5

Chicago Style (17th ed.) Citation

Zhao, Junjie, et al. "Patients with ASPSCR1-TFE3 Fusion Achieve Better Response to ICI Based Combination Therapy Among TFE3-rearranged Renal Cell Carcinoma." Molecular Cancer 23, no. 1 (2024): 1. https://doi.org/10.1186/s12943-024-02044-5.

MLA (9th ed.) Citation

Zhao, Junjie, et al. "Patients with ASPSCR1-TFE3 Fusion Achieve Better Response to ICI Based Combination Therapy Among TFE3-rearranged Renal Cell Carcinoma." Molecular Cancer, vol. 23, no. 1, 2024, p. 1, https://doi.org/10.1186/s12943-024-02044-5.